This HTML delivers a complete FAQ article for China-Gateway 360, tailored for foreign executives exploring M&A in China. It uses a Q&A format with
tags for each question and
blocks for detailed answers, incorporating real data points and pinyin for key Chinese terms. The content covers regulatory approvals, due diligence, valuation trends, and post-merger integration, aiming to equip readers with practical, data-backed insights for strategic decision-making.
“`html
M&A
1 What is the current state of M&A in China?
China’s M&A market in 2024–2025 is characterised by selective consolidation and a shift toward quality over quantity. Total announced M&A value in China reached approximately USD 380 billion in 2024 (refinitiv data), down roughly 12% from the 2021 peak but still the second-largest market in Asia after the US. Cross-border inbound M&A—deals where foreign companies acquire Chinese targets—accounted for about USD 42 billion, with particular activity in advanced manufacturing, healthcare, and clean energy.
Data point: According to the China Ministry of Commerce (MOFCOM, 商务部 Shāngwùbù), foreign-invested enterprises (FIEs) conducted 1,386 M&A transactions in 2024, up 9% year-on-year, signalling a steady recovery in foreign acquirer confidence.
Foreign executives should note that the era of rapid, highly leveraged buyouts is being replaced by strategic, operationally focused acquisitions—often in sectors aligned with China’s “New Quality Productive Forces” (新质生产力 xīn zhì shēngchǎn lì) policy framework.
2 Which regulatory approvals do foreign buyers need?
A typical China M&A deal involving a foreign acquirer triggers up to four parallel review streams:
① National Security Review (国家安全审查 guójiā ānquán shěnchá) – administered by the Office of the National Security Review Mechanism (jointly led by NDRC and MOFCOM). Mandatory for deals in defence, critical infrastructure, data security, and key technologies. In 2024, the review scope expanded to include “sensitive personal data” and “critical information infrastructure operators.”
② Anti-monopoly Review (反垄断审查 fǎn lǒngduàn shěnchá) – conducted by the State Administration for Market Regulation (SAMR, 国家市场监督管理总局). Any transaction meeting SAMR’s turnover thresholds (e.g. global turnover > CNY 10 billion, or China turnover > CNY 2 billion) must be notified. Average review timeline: 90–180 days.
③ Sector-specific approvals – for industries such as finance (CBIRC), securities (CSRC), telecoms (MIIT), or healthcare (NMPA).
④ Foreign Investment Negative List – if the target operates in a restricted sector, the acquirer must comply with equity caps or additional licensing (see Q3).
3 How does the Negative List affect deal structuring?
The Special Administrative Measures (Negative List) for Foreign Investment Access (外商投资准入负面清单 wàishāng tóuzī zhǔnrù fùmiàn qīngdān) is the single most important document for foreign M&A structuring. The 2024 edition reduced restricted items to 31 (from 48 in 2017). Key restricted sectors include:
- Telecommunications – value-added services capped at 50% foreign ownership (exceptions for certain pilot zones).
- Education – compulsory education remains prohibited.
- Media & publishing – foreign equity generally limited to 49%.
- Healthcare – hospitals can be 100% foreign-owned in most regions, but with operational restrictions.
For unrestricted sectors, 100% foreign acquisition is allowed, but the deal still requires standard registration with MOFCOM and the local Administration for Market Regulation. A common workaround for restricted sectors is the VIE (Variable Interest Entity) structure (可变利益实体 kě biàn lìyì shítǐ), though regulatory uncertainty around VIE has increased since 2023.
4 What does SAMR focus on in M&A reviews?
The State Administration for Market Regulation (SAMR) applies a competition test similar to the EU and US, but with a distinct Chinese flavour. In 2024, SAMR reviewed 342 transactions, approving 330 unconditionally, 10 with remedies, and blocking 2. Key focus areas:
• Market concentration – if the merged entity holds >40% share in a relevant market, remedies (e.g. divestiture, firewalling) are likely.
• Industrial policy alignment – SAMR increasingly considers whether the deal supports “national strategy” (国家战略 guójiā zhànlüè) such as semiconductor self-sufficiency or carbon neutrality. Deals in AI, EVs, and biotech get enhanced scrutiny.
• Procedural compliance – failure to notify a notifiable transaction can result in fines up to 10% of the undertaking’s annual turnover in China. At least two foreign firms were fined in 2024 for gun-jumping.
5 How has the National Security Review evolved?
The National Security Review (NSR) regime was tightened by the Regulations on the Security Review of Foreign Investment (2020, amended 2023). The 2023 amendments expanded jurisdiction to include:
- Acquisitions involving personal data of more than 1 million users.
- Investments near military or dual-use facilities.
- Deals that give a foreign investor the ability to control or materially influence a Chinese company’s operations.
In 2024, roughly 15% of foreign M&A deals by value triggered an NSR filing. The review timeline is officially 120 working days, but can extend to 180 days. Practically, deals that raise national security concerns often proceed with mitigation agreements (e.g. data localisation, no cross-border technology transfer).
Data point: In 2024, the NSR office blocked 3 deals outright—two in semiconductor equipment and one in geospatial data services.
6 What due diligence areas are unique to China?
Beyond legal, financial, and commercial due diligence, foreign acquirers in China must prioritise:
• Regulatory compliance (合规 héguī) – verify that the target holds all required ICP licences, data security filings, and sector-specific permits. Licence gaps are common in tech and healthcare.
• Data and cybersecurity – under the Personal Information Protection Law (PIPL, 个人信息保护法) and the Data Security Law (数据安全法), any target processing significant
